Sonnet BioTherapeutics Holdings, Inc.
SONN
$4.89
-$0.96-16.41%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -7.71% | -1,055.42% | -170.49% | 14.91% | 11.18% |
| Total Depreciation and Amortization | 5.71% | 7.80% | 11.00% | 10.77% | 10.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -68.03% | 706.79% | 16.77% | 20.80% | 96.64% |
| Change in Net Operating Assets | 10,647.16% | 83.93% | 107.77% | 87.01% | 99.29% |
| Cash from Operations | 42.70% | -441.43% | 5.87% | 30.46% | 50.27% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | -- | -- | 100.00% | 0.00% |
| Cash from Investing | 100.00% | -- | -- | 100.00% | 0.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.63% | -8.57% | 100.87% | -- | 65.63% |
| Repurchase of Common Stock | -- | -- | -- | -23.16% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 87.30% | -2,368.00% | -- | -- | -- |
| Cash from Financing | -99.26% | -878.05% | 98.55% | -1,225.99% | 57.02% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -649.46% | -466.40% | 530.71% | 28.27% | 94.69% |